Table 3.
Association between serum cholesterol concentration and prostate cancer, placebo arm of the Prostate Cancer Prevention Trial
| Quintile of serum cholesterol concentration |
P-trend | Serum cholesterol concentration < 200 versus ≥ 200 mg/dL |
|||||
|---|---|---|---|---|---|---|---|
| 1 | 2 | 3 | 4 | 5 | |||
| Total prostate cancer (N) | 245 | 232 | 252 | 262 | 260 | ||
| ORage-adjusted (95% CI) |
0.93 (0.76, 1.13) |
0.89 (0.73, 1.09) |
0.90 (0.74, 1.09) |
1.02 (0.84, 1.24) |
1.00 (ref) |
0.37 | 0.96 (0.85, 1.10) |
| ORmultivariable-adjusted* (95% CI) |
0.94 (0.77, 1.15) |
0.90 (0.74, 1.10) |
0.90 (0.74, 1.09) |
1.03 (0.85, 1.25) |
1.00 (ref) |
0.43 | 0.97 (0.85, 1.11) |
| Organ-confined disease (N) | 215 | 209 | 222 | 233 | 245 | ||
| ORage-adjusted (95% CI) |
0.87 (0.71, 1.06) |
0.85 (0.70, 1.05) |
0.84 (0.69, 1.03) |
0.97 (0.79, 1.18) |
1.00 (ref) |
0.14 | 0.95 (0.83, 1.08) |
| ORmultivariable-adjusted* (95% CI) |
0.88 (0.72, 1.08) |
0.86 (0.70, 1.06) |
0.83 (0.68, 1.02) |
0.97 (0.80, 1.19) |
1.00 (ref) |
0.17 | 0.96 (0.84, 1.10) |
| Gleason 2-6 (N) | 204 | 185 | 196 | 204 | 204 | ||
| ORage-adjusted (95% CI) |
0.99 (0.80, 1.22) |
0.91 (0.73, 1.13) |
0.89 (0.72, 1.10) |
1.01 (0.82, 1.25) |
1.00 (ref) |
0.85 | 1.01 (0.88, 1.17) |
| ORmultivariable-adjusted* (95% CI) |
1.00 (0.81, 1.24) |
0.91 (0.73, 1.13) |
0.88 (0.71, 1.09) |
1.02 (0.82, 1.26) |
1.00 (ref) |
0.94 | 1.03 (0.89, 1.18) |
| Gleason 7-10 (N) | 41 | 47 | 56 | 58 | 56 | ||
| ORage-adjusted (95% CI) |
0.72 (0.48, 1.09) |
0.86 (0.57, 1.28) |
0.94 (0.64, 1.37) |
1.07 (0.74, 1.57) |
1.00 (ref) |
0.07 | 0.79 (0.60, 1.03) |
| ORmultivariable-adjusted* (95% CI) |
0.70 (0.46, 1.07) |
0.88 (0.59, 1.31) |
0.95 (0.65, 1.39) |
1.08 (0.74, 1.58) |
1.00 (ref) |
0.07 | 0.78 (0.60, 1.02) |
| Gleason 7 (N) | 34 | 41 | 45 | 37 | 42 | ||
| ORage-adjusted (95% CI) |
0.80 (0.51, 1.27) |
1.00 (0.64, 1.55) |
1.01 (0.66, 1.55) |
0.91 (0.58, 1.43) |
1.00 (ref) |
0.50 | 0.93 (0.69, 1.24) |
| ORmultivariable-adjusted* (95% CI) |
0.79 (0.49, 1.25) |
1.02 (0.66, 1.59) |
1.01 (0.66, 1.56) |
0.92 (0.59, 1.44) |
1.00 (ref) |
0.49 | 0.93 (0.69, 1.24) |
| Gleason 8-10 (N) | 7 | 6 | 11 | 21 | 14 | ||
| ORage-adjusted (95% CI) |
0.48 (0.19, 1.20) |
0.43 (0.17, 1.14) |
0.73 (0.33, 1.62) |
1.55 (0.78, 3.08) |
1.00 (ref) |
0.01 | 0.42 (0.22, 0.77) |
| ORmultivariable-adjusted* (95% CI) |
0.46 (0.18, 1.16) |
0.45 (0.17, 1.17) |
0.75 (0.33, 1.66) |
1.53 (0.77, 3.05) |
1.00 (ref) |
0.01 | 0.41 (0.22, 0.77) |
*
Adjusted for age, race, family history of prostate cancer, BMI, diabetes, regular aspirin use, and history of heart attack.